I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.
I-123 metaiodobenzylguanidine (MIBG) scintigraphy is a new method to evaluate cardiac sympathetic nerve disturbance in patients with diabetes mellitus. Epalrestat specifically inhibits aldose reductase and improves diabetic neuropathy. The authors report a case of improvement in cardiac sympathetic dysfunction using MIBG scintigraphy with epalrestat therapy. In this case, epalrestat effectively reversed diabetic neuropathy, and MIBG scintigraphy was useful to evaluate the effect of epalrestat.
Utsunomiya
K
K
Department of Radiology, Osaka Medical College, Japan. keitau@interlog.com
Narabayashi
I
I
Nakatani
Y
Y
Tamura
K
K
Onishi
S
S
D019797:3-Iodobenzylguanidine; D000328:Adult; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D001342:Autonomic Nervous System Diseases / Q000000981:diagnostic imaging*; D003929:Diabetic Neuropathies / Q000000981:diagnostic imaging* / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006321:Heart / Q000000981:diagnostic imaging* / Q000294:innervation; D006801:Humans; D008297:Male; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012236:Rhodanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D053778:Thiazolidines
D004791:Enzyme Inhibitors; D019275:Radiopharmaceuticals; D053778:Thiazolidines; D019797:3-Iodobenzylguanidine; C038131:epalrestat; D012236:Rhodanine; D000449:Aldehyde Reductase